FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069012743> ?p ?o ?g. }

• W2069012743 endingPage "2569" @default.
• W2069012743 startingPage "2562" @default.
• W2069012743 abstract "BACKGROUND Both locoregional and distant disease control remains poor in the treatment of Stage III nonsmall cell lung carcinoma (NSCLC). This trial was conducted to evaluate the tolerance and responses of patients with NSCLC given a neoadjuvant regimen of cisplatin and vinorelbine chemotherapy followed by accelerated thoracic radiotherapy. METHODS Forty-two patients with Stage IIIA and IIIB NSCLC were entered into the study. Treatment consisted of cisplatin 100 mg/m2 given on Days 1 and 29 and vinorelbine 30 mg/m2 given weekly for 5 weeks, with a planned 50% dose reduction to 15 mg/m2 planned for Week 2. This was followed by thoracic irradiation of 60 gray (Gy) in 30 fractions of 2 Gy over 4 weeks (once daily during Weeks 1 and 2 and twice daily during Weeks 3 and 4). RESULTS With a median follow-up time of 12.2 months (27–65 months for survivors), the median survival was 12.2 months (16.6 months for patients with no prior weight loss and 7.8 months for those with prior weight loss). The response rate after induction chemotherapy was 46.1%, increasing to 74.4% after radiation therapy (8 complete responses and 21 partial responses). The rate of progression was 13 of 18 (72%) for those who responded to chemotherapy (4 distant, 9 local) and 18 of 21 (86%) for those who did not respond to chemotherapy (14 distant, 7 local). The most frequent acute Grade 3 toxicity was nausea (21.4%). CONCLUSIONS Accelerated thoracic irradiation after induction chemotherapy is well tolerated and yields therapeutic results that compare favorably with those reported for other regimens of chemotherapy and standard fractionated radiotherapy. The data from this study suggest that the responses of patients with clinically apparent disease to induction chemotherapy might indicate a likelihood of controlling microscopic distant metastases. Cancer 1999;85:2562–9. © 1999 American Cancer Society." @default.
• W2069012743 created "2016-06-24" @default.
• W2069012743 creator A5011406689 @default.
• W2069012743 creator A5020638079 @default.
• W2069012743 creator A5024741202 @default.
• W2069012743 creator A5025499814 @default.
• W2069012743 creator A5035605611 @default.
• W2069012743 creator A5042828527 @default.
• W2069012743 creator A5066833375 @default.
• W2069012743 creator A5067663053 @default.
• W2069012743 creator A5076058689 @default.
• W2069012743 creator A5081220338 @default.
• W2069012743 creator A5081974555 @default.
• W2069012743 date "1999-06-15" @default.
• W2069012743 modified "2023-10-15" @default.
• W2069012743 title "A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma" @default.
• W2069012743 cites W1837121308 @default.
• W2069012743 cites W1975081329 @default.
• W2069012743 cites W2000730161 @default.
• W2069012743 cites W2011447425 @default.
• W2069012743 cites W2014145691 @default.
• W2069012743 cites W2034840803 @default.
• W2069012743 cites W2039492672 @default.
• W2069012743 cites W2042035608 @default.
• W2069012743 cites W2045313863 @default.
• W2069012743 cites W2051767374 @default.
• W2069012743 cites W2055228153 @default.
• W2069012743 cites W2073407568 @default.
• W2069012743 cites W2083766301 @default.
• W2069012743 cites W2105150213 @default.
• W2069012743 cites W2129793485 @default.
• W2069012743 cites W2138310931 @default.
• W2069012743 cites W2138945505 @default.
• W2069012743 cites W2149787575 @default.
• W2069012743 cites W2167805334 @default.
• W2069012743 cites W2226077283 @default.
• W2069012743 cites W2256453366 @default.
• W2069012743 cites W2261464614 @default.
• W2069012743 cites W2317448174 @default.
• W2069012743 cites W4239714259 @default.
• W2069012743 cites W4293241248 @default.
• W2069012743 doi "https://doi.org/10.1002/(sici)1097-0142(19990615)85:12<2562::aid-cncr11>3.0.co;2-d" @default.
• W2069012743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10375103" @default.
• W2069012743 hasPublicationYear "1999" @default.
• W2069012743 type Work @default.
• W2069012743 sameAs 2069012743 @default.
• W2069012743 citedByCount "16" @default.
• W2069012743 crossrefType "journal-article" @default.
• W2069012743 hasAuthorship W2069012743A5011406689 @default.
• W2069012743 hasAuthorship W2069012743A5020638079 @default.
• W2069012743 hasAuthorship W2069012743A5024741202 @default.
• W2069012743 hasAuthorship W2069012743A5025499814 @default.
• W2069012743 hasAuthorship W2069012743A5035605611 @default.
• W2069012743 hasAuthorship W2069012743A5042828527 @default.
• W2069012743 hasAuthorship W2069012743A5066833375 @default.
• W2069012743 hasAuthorship W2069012743A5067663053 @default.
• W2069012743 hasAuthorship W2069012743A5076058689 @default.
• W2069012743 hasAuthorship W2069012743A5081220338 @default.
• W2069012743 hasAuthorship W2069012743A5081974555 @default.
• W2069012743 hasBestOaLocation W20690127431 @default.
• W2069012743 hasConcept C126322002 @default.
• W2069012743 hasConcept C141071460 @default.
• W2069012743 hasConcept C143998085 @default.
• W2069012743 hasConcept C2776611710 @default.
• W2069012743 hasConcept C2776694085 @default.
• W2069012743 hasConcept C2778239845 @default.
• W2069012743 hasConcept C2779562246 @default.
• W2069012743 hasConcept C2780350996 @default.
• W2069012743 hasConcept C2780580376 @default.
• W2069012743 hasConcept C2781413609 @default.
• W2069012743 hasConcept C45393284 @default.
• W2069012743 hasConcept C500558357 @default.
• W2069012743 hasConcept C509974204 @default.
• W2069012743 hasConcept C71924100 @default.
• W2069012743 hasConcept C90924648 @default.
• W2069012743 hasConceptScore W2069012743C126322002 @default.
• W2069012743 hasConceptScore W2069012743C141071460 @default.
• W2069012743 hasConceptScore W2069012743C143998085 @default.
• W2069012743 hasConceptScore W2069012743C2776611710 @default.
• W2069012743 hasConceptScore W2069012743C2776694085 @default.
• W2069012743 hasConceptScore W2069012743C2778239845 @default.
• W2069012743 hasConceptScore W2069012743C2779562246 @default.
• W2069012743 hasConceptScore W2069012743C2780350996 @default.
• W2069012743 hasConceptScore W2069012743C2780580376 @default.
• W2069012743 hasConceptScore W2069012743C2781413609 @default.
• W2069012743 hasConceptScore W2069012743C45393284 @default.
• W2069012743 hasConceptScore W2069012743C500558357 @default.
• W2069012743 hasConceptScore W2069012743C509974204 @default.
• W2069012743 hasConceptScore W2069012743C71924100 @default.
• W2069012743 hasConceptScore W2069012743C90924648 @default.
• W2069012743 hasIssue "12" @default.
• W2069012743 hasLocation W20690127431 @default.
• W2069012743 hasLocation W20690127432 @default.
• W2069012743 hasOpenAccess W2069012743 @default.
• W2069012743 hasPrimaryLocation W20690127431 @default.
• W2069012743 hasRelatedWork W2006192033 @default.
• W2069012743 hasRelatedWork W2085142786 @default.
• W2069012743 hasRelatedWork W2106933094 @default.

• next